A study led by UT Southwestern dermatologists suggests that a common inflammatory skin condition may stem from poorly regulated hormones. The finding could offer an unexpected new target to fight this condition.

Atopic dermatitis (AD) is a form of eczema. AD affects up to 13% of children and 10% of adults, with an annual treatment cost of $5.3 billion in the U.S. alone.

"We often think of eczema as a dry-skin condition and treat mild cases with moisturizers," said corresponding author Tamia Harris-Tryon at UTSW. "Here, we're showing that a gene that's important for making hormones seems to play a role in the skin making its own moisturizers.

"If we could alter this gene's activity, we could potentially provide relief to eczema patients by helping the skin make more oils and lipids to moisturize itself."

Dr. Harris-Tryon explained that previous research has linked AD to overactivity in genes responsible for the production of two inflammatory immune molecules, interleukins 4 and 13 (IL-4 and IL-13).

A relatively new drug called dupilumab-a monoclonal antibody that reduces the amount of the inflammatory molecules-has been extremely effective in many patients with moderate to severe AD. However, the molecular mechanisms behind how IL-4 and IL-13 contribute to this form of eczema was unknown.

To investigate this question, Dr. Harris-Tryon and her colleagues focused on sebocytes, the cells that make up sebaceous glands. These glands produce an oily, waxy barrier that coats the skin, helping it retain moisture.

The researchers dosed human sebocytes growing in petri dishes with IL-4 and IL-13, then used a technique called RNA sequencing to get a readout on gene activity for the entire genome and compared it with gene activity in sebocytes that weren't treated with these immune molecules.

They found that a gene called HSD3B1, which makes an enzyme called 3b-hydroxysteroid dehydrogenase 1, became up to 60 times more active when exposed to the two interleukins.

Atopic dermatitis (AD) is a form of eczema. AD affects up to 13% of children and 10% of adults, with an annual treatment cost of $5.3 billion in the U.S. alone.

"We often think of eczema as a dry-skin condition and treat mild cases with moisturizers," said corresponding author Tamia Harris-Tryon at UTSW. "Here, we're showing that a gene that's important for making hormones seems to play a role in the skin making its own moisturizers.

"If we could alter this gene's activity, we could potentially provide relief to eczema patients by helping the skin make more oils and lipids to moisturize itself."

Dr. Harris-Tryon explained that previous research has linked AD to overactivity in genes responsible for the production of two inflammatory immune molecules, interleukins 4 and 13 (IL-4 and IL-13).

A relatively new drug called dupilumab-a monoclonal antibody that reduces the amount of the inflammatory molecules-has been extremely effective in many patients with moderate to severe AD. However, the molecular mechanisms behind how IL-4 and IL-13 contribute to this form of eczema was unknown.

To investigate this question, Dr. Harris-Tryon and her colleagues focused on sebocytes, the cells that make up sebaceous glands. These glands produce an oily, waxy barrier that coats the skin, helping it retain moisture.

The researchers dosed human sebocytes growing in petri dishes with IL-4 and IL-13, then used a technique called RNA sequencing to get a readout on gene activity for the entire genome and compared it with gene activity in sebocytes that weren't treated with these immune molecules.

They found that a gene called HSD3B1, which makes an enzyme called 3b-hydroxysteroid dehydrogenase 1, became up to 60 times more active when exposed to the two interleukins.

The finding was a surprise, Dr. Harris-Tryon said, because this enzyme is well known for playing a key role in the production of hormones such as testosterone and progesterone, but it had never been linked to atopic dermatitis and skin lipid production.

Databases of human gene activity showed that HSD3B1 tends to be overactive in patients with eczema; a single study of patients on dupilumab showed that this drug appears to lower HSD3B1‘s activity. Both pieces of evidence suggest that IL-4 and IL-13 drive up the activity of this gene.

To determine how this gene affects sebum output, the researchers manipulated HSD3B1‘s activity in sebocytes growing in petri dishes. They found that when they made this gene less active, the levels of hormones decreased, and skin sebum production increased.

The reverse was also true, with more gene activity leading to higher amounts of hormones and less sebum. The researchers made similar findings in a mouse model of AD, with hormone production decreasing the production of skin lipids.

Together, Dr. Harris-Tryon said, these findings-published in TNAS, suggest that HSD3B1 could be a new target for fighting AD and potentially other forms of eczema.

"Changing the output of this gene could eventually offer a way to treat AD that's completely different from any treatment that currently exists," she added. That's an exciting breakthrough indeed.

Source: UT Southwestern Medical Center

GIVE HOPE to Your Chums Who'd Love to Hear This News…